nach oben

American Journal of Clinical Dermatology

Erschienen in:

01.08.2007 | Review Article

Dermatologic Manifestations of Polycystic Ovary Syndrome

verfasst von: Amy T. Lee, Dr Lee T. Zane

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

Polycystic ovary syndrome (PCOS) affects 5-10% of reproductive-aged women and is one of the most common endocrine disorders in women. The disorder is commonly characterized by elevated levels of androgen and insulin. Women with PCOS may present with a range of signs and symptoms, and face increased risks of reproductive, metabolic, cardiovascular, psychologic, and neoplastic sequelae, particularly if the condition is left unrecognized or untreated. The clinical definition of PCOS has changed in recent years and includes as one of its cardinal criteria the dermatologic manifestations of hyperandrogenism, chiefly hirsutism, acne vulgaris, and androgenetic alopecia. Acanthosis nigricans, a cutaneous sign of hyperinsulinemia, may also be present. These dermatologic features may provide early clinical clues to recognition of PCOS, and treatment of these cutaneous conditions may improve the patient’s quality of life and psychologic well-being. The effects of androgen on pilosebaceous units in the skin can vary by anatomic location, producing pathophysiologic effects on hair growth and differentiation, sebaceous gland size and activity, and follicular keratinization. Treatment modalities may include hormonal therapy intended to modulate androgen production and action as well as non-hormonal therapies directed toward specific dermatologic conditions.

Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352 (12): 1223–36PubMedCrossRef

Azziz R, Marin C, Hoq L, et al. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab 2005; 90 (8): 4650–8PubMedCrossRef

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19 (1): 41–7

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81 (1): 19–25

Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, et al., editors. Polycystic ovary syndrome.Boston (MA): Blackwell Scientific, 1992: 377–84

Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab 2006; 91 (3): 781–5PubMedCrossRef

Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91 (11): 4237–45PubMedCrossRef

Nelson VL, Legro RS, Strauss 3rd JF, et al. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 1999; 13 (6): 946–57PubMedCrossRef

Nelson VL, Qin KN, Rosenfield RL, et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001; 86 (12): 5925–33PubMedCrossRef

10.

Eagleson CA, Gingrich MB, Pastor CL, et al. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 2000; 85 (11): 4047–52PubMedCrossRef

11.

Fauser BC, Pache TD, Lamberts SW, et al. Serum bioactive and immunoreactive luteinizing hormone and follicle stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease. SJ Clin Endocrinol Metab 1991; 73 (4): 811–7CrossRef

12.

Taylor AE, McCourt B, Martin KA, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82 (7): 2248–56PubMedCrossRef

13.

Bergh C, Carlsson B, Olsson JH, et al. Regulation of androgen production in cultured human theca cells by insulin like growth factor I and insulin. Fertil Steril 1993; 59 (2): 323–31PubMed

14.

Poretsky L, Cataldo NA, Rosenwaks Z, et al. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999; 20 (4): 535–82PubMedCrossRef

15.

Rodin DA, Bano G, Bland JM, et al. Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women. Clin Endocrinol (Oxf) 1998; 49 (1): 91–9CrossRef

16.

Diamanti-Kandarakis E, Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Hum Reprod Update 2005; 11 (6): 631–43PubMedCrossRef

17.

Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 2005; 26 (2): 251–82PubMedCrossRef

18.

Hoeger KM. Role of lifestyle modification in the management of polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab 2006; 20 (2): 293–310PubMedCrossRef

19.

Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992; 36 (1): 105–11CrossRef

20.

Dunaif A, Segal KR, Futterweit W, et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38 (9): 1165–74PubMedCrossRef

21.

Norman RJ, Davies MJ, Lord J, et al. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 2002; 13 (6): 251–7PubMedCrossRef

22.

Carmina E, Rosato F, Janni A, et al. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 2006; 91 (1): 2–6PubMedCrossRef

23.

Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001; 86 (4): 1626–32PubMedCrossRef

24.

Wang JX, Davies MJ, Norman RJ. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum Reprod 2001; 16 (12): 2606–9PubMedCrossRef

25.

Schieve LA, Tatham L, Peterson HB, et al. Spontaneous abortion among pregnancies conceived using assisted reproductive technology in the United States. Obstet Gynecol 2003; 101 (5 Pt 1): 959–67PubMedCrossRef

26.

Winter E, Wang J, Davies MJ, et al. Early pregnancy loss following assisted reproductive technology treatment. Hum Reprod 2002; 17 (12): 3220–3PubMedCrossRef

27.

Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003; 361 (9371): 1810–2PubMedCrossRef

28.

Giangrande PH, Kimbrel EA, Edwards DP, et al. The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol 2000; 20 (9): 3102–15PubMedCrossRef

29.

Hanekamp EE, Gielen SC, Smid-Koopman E, et al. Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer. Clin Cancer Res 2003; 9 (11): 4190–9PubMed

30.

Konishi I, Koshiyama M, Mandai M, et al. Increased expression of LH/hCG receptors in endometrial hyperplasia and carcinoma in anovulatory women. Gynecol Oncol 1997; 65 (2): 273–80PubMedCrossRef

31.

Lincoln SR, Lei ZM, Rao CV, et al. The expression of human chorionic gonado-tropin/human luteinizing hormone receptors in ectopic human endometrial implants. J Clin Endocrinol Metab 1992; 75 (4): 1140–4PubMedCrossRef

32.

Dahlgren E, Friberg LG, Johansson S, et al. Endometrial carcinoma; ovarian dysfunction: a risk factor in young women. Eur J Obstet Gynecol Reprod Biol 1991; 41 (2): 143–50PubMedCrossRef

33.

Dahlgren E, Johansson S, Oden A, et al. A model for prediction of endometrial cancer. Acta Obstet Gynecol Scand 1989; 68 (6): 507–10PubMed

34.

Elwood JM, Cole P, Rothman KJ, et al. Epidemiology of endometrial cancer. J Natl Cancer Inst 1977; 59 (4): 1055–60PubMed

35.

Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Update 2001; 7 (6): 522–5PubMedCrossRef

36.

Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84 (1): 165–9PubMedCrossRef

37.

Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22 (1): 141–6PubMedCrossRef

38.

Christian RC, Dumesic DA, Behrenbeck T, et al. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88 (6): 2562–8PubMedCrossRef

39.

Talbott EO, Zborowski JV, Sutton-Tyrrell K, et al. Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001; 28 (1): 111–33, viiPubMedCrossRef

40.

Talbott E, Guzick D, Clerici A, et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995; 15 (7): 821–6PubMedCrossRef

41.

Ehrmann DA, Liljenquist DR, Kasza K, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91 (1): 48–53PubMedCrossRef

42.

Essah PA, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. J Endocrinol Invest 2006; 29 (3): 270–80PubMed

43.

Cronin L, Guyatt G, Griffith L, et al. Development of a health-related quality-of- life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 1998; 83 (6): 1976–87PubMedCrossRef

44.

Jones GL, Benes K, Clark TL, et al. The Polycystic Ovary Syndrome health-related quality of life Questionnaire (PCOSQ): a validation. Hum Reprod 2004; 19 (2): 371–7PubMedCrossRef

45.

Coffey S, Bano G, Mason HD. Health-related quality of life in women with polycystic ovary syndrome: a comparison with the general population using the Polycystic Ovary Syndrome Questionnaire (PCOSQ) and the Short Form-36 (SF-36). Gynecol Endocrinol 2006; 22 (2): 80–6PubMedCrossRef

46.

Hahn S, Janssen OE, Tan S, et al. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome.Eur J Endocrinol 2005; 153 (6): 853–60PubMedCrossRef

47.

Lasek RJ, Chren MM. Acne vulgaris and the quality of life of adult dermatology patients. Arch Dermatol 1998; 134 (4): 454–8PubMedCrossRef

48.

Martin AR, Lookingbill DP, Botek A, et al. Health-related quality of life among patients with facial acne: assessment of a new acne-specific questionnaire. Clin Exp Dermatol 2001; 26 (5): 380–5PubMedCrossRef

49.

Hahn S, Benson S, Elsenbruch S, et al. Metformin treatment of polycystic ovary syndrome improves health-related quality-of-life, emotional distress and sexuality. Hum Reprod 2006; 21 (7): 1925–34PubMedCrossRef

50.

Weiner CL, Primeau M, Ehrmann DA. Androgens and mood dysfunction in women: comparison of women with polycystic ovarian syndrome to healthy controls. Psychosom Med2004; 66 (3): 356–62PubMedCrossRef

51.

Elsenbruch S, Hahn S, Kowalsky D, et al. Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88 (12): 5801–7PubMedCrossRef

52.

Himelein MJ, Thatcher SS. Depression and body image among women with polycystic ovary syndrome. J Health Psychol 2006; 11 (4): 613–25PubMedCrossRef

53.

Rasgon NL, Rao RC, Hwang S, et al. Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. J Affect Disord 2003; 74 (3): 299–304PubMedCrossRef

54.

Keegan A, Liao LM, Boyle M.Hirsutism’: a psychological analysis. J Health Psychol 2003; 8 (3): 327–45PubMed

55.

Elsenbruch S, Benson S, Hahn S, et al. Determinants of emotional distress in women with polycystic ovary syndrome. Hum Reprod 2006; 21 (4): 1092–9PubMedCrossRef

56.

McCluskey S, Evans C, Lacey JH, et al. Polycystic ovary syndrome and bulimia. Fertil Steril 1991; 55 (2): 287–91PubMed

57.

Naessen S, Carlstrom K, Garoff L, et al. Polycystic ovary syndrome in bulimic women: an evaluation based on the new diagnostic criteria. Gynecol Endocrinol 2006 Jul; 22 (7): 388–94PubMedCrossRef

58.

Stice E, Hayward C, Cameron RP, et al. Body-image and eating disturbances predict onset of depression among female adolescents: a longitudinal study. J Abnorm Psychol 2000; 109 (3): 438–44PubMedCrossRef

59.

Boots LR, Potter S, Potter D, et al. Measurement of total serum testosterone levels using commercially available kits: high degree of between-kit variability. Fertil Steril 1998; 69 (2): 286–92PubMedCrossRef

60.

Rosner W. Errors in the measurement of plasma free testosterone. J Clin Endocrinol Metab 1997; 82 (6): 2014–5PubMed

61.

Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84 (10): 3666–72PubMedCrossRef

62.

Goodman NF, Bledsoe MB, Futterweit W, et al. American Association of Clinical Endocrinologists medical guidelines for the clinical practice for the diagnosis and treatment of hyperandrogenic disorders. Endocr Pract 2001; 7 (2): 120–34PubMed

63.

ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists: number 41, December dy2002. Obstet Gynecol 2002; 100 (6): 1389–402

64.

Menon GK, Feingold KR, Moser AH, et al. De novo sterologenesis in the skin: II.Regulation by cutaneous barrier requirements. J Lipid Res 1985; 26 (4): 418–27PubMed

65.

Smythe CD, Greenall M, Kealey T. The activity of HMG-CoA reductase and acetyl-CoA carboxylase in human apocrine sweat glands, sebaceous glands, and hair follicles is regulated by phosphorylation and by exogenous cholesterol. J Invest Dermatol 1998; 111 (1): 139–48PubMedCrossRef

66.

Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol 2004; 22 (5): 419–28PubMedCrossRef

67.

Choudhry R, Hodgins MB, Van der Kwast TH, et al. Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol 1992; 133 (3): 467–75PubMedCrossRef

68.

Liang T, Hoyer S, Yu R, et al. Immunocytochemical localization of androgen receptors in human skin using monoclonal antibodies against the androgen receptor. J Invest Dermatol 1993; 100 (5): 663–6PubMedCrossRef

69.

Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev 2000; 21 (4): 363–92PubMedCrossRef

70.

Olsen EA. Disorders of hair growth: diagnosis and treatment. 2nd ed. New York: McGraw-Hill Professional, 2003

71.

Guarrera M, Rebora A. Anagen hairs may fail to replace telogen hairs in early androgenetic female alopecia. Dermatology 1996; 192 (1): 28–31PubMedCrossRef

72.

Courtois M, Loussouarn G, Hourseau C, et al. Ageing and hair cycles. Br J Dermatol 1995; 132 (1): 86–93PubMedCrossRef

73.

Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49 (1 Suppl.): S1–37PubMedCrossRef

74.

Pochi PE, Strauss JS. Endocrinologic control of the development and activity of the human sebaceous gland. J Invest Dermatol 1974; 62 (3): 191–201PubMedCrossRef

75.

Pochi PE, Strauss JS, Downing DT. Age-related changes in sebaceous gland activity. J Invest Dermatol 1979; 73 (1): 108–11PubMedCrossRef

76.

Sonino N, Fava GA, Mani E, et al. Quality of life of hirsute women. Postgrad Med J 1993; 69 (809): 186–9PubMedCrossRef

77.

Chang WY, Knochenhauer ES, Bartolucci AA, et al. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril 2005; 83 (6): 1717–23PubMedCrossRef

78.

Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89 (6): 2745–9PubMedCrossRef

79.

Hatch R, Rosenfield RL, Kim MH, et al. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981; 140 (7): 815–30PubMed

80.

Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83 (9): 3078–82PubMedCrossRef

81.

Wijeyaratne CN, Balen AH, Barth JH, et al. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? Clin Endocrinol(Oxf) 2002; 57 (3): 343–50CrossRef

82.

Carmina E, Koyama T, Chang L, et al. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol 1992; 167 (6): 1807–12PubMed

83.

Diani AR, Mulholland MJ, Shull KL, et al. Hair growth effects of oral administration of finasteride, a steroid 5 alpha-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque. J Clin Endocrinol Metab 1992; 74 (2): 345–50PubMedCrossRef

84.

Barth JH. Semi-quantitative measurements of body hair in hirsute women compare well with direct diameter measurements of hair shafts. Acta Derm Venereol 1997; 77 (4): 317–8PubMed

85.

Ehrmann DA, Rosenfield RL. Clinical review 10: an endocrinologic approach to the patient with hirsutism. J Clin Endocrinol Metab 1990; 71 (1): 1–4PubMedCrossRef

86.

Reingold SB, Rosenfield RL. The relationship of mild hirsutism or acne in women to androgens. Arch Dermatol 1987; 123 (2): 209–12PubMedCrossRef

87.

Borgia F, Cannavo S, Guarneri F, et al. Correlation between endocrinological parameters and acne severity in adult women. Acta Derm Venereol 2004; 84 (3): 201–4PubMedCrossRef

88.

Falsetti L, Gambera A, Andrico S, et al. Acne and hirsutism in polycystic ovary syndrome: clinical, endocrine-metabolic and ultrasonographic differences. Gynecol Endocrinol 2002; 16 (4): 275–84PubMed

89.

Rosenfield RL. Clinical practice: hirsutism. N Engl J Med 2005; 353 (24): 2578–88PubMedCrossRef

90.

Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004; 89 (2): 453–62PubMedCrossRef

91.

Dramusic V, Rajan U, Chan P, et al. Adolescent polycystic ovary syndrome. Ann N Y Acad Sci 1997; 816: 194–208PubMedCrossRef

92.

Timpatanapong P, Rojanasakul A. Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne. J Dermatol 1997; 24 (4): 223–9PubMed

93.

Bunker CB, Newton JA, Kilborn J, et al. Most women with acne have polycystic ovaries. Br J Dermatol 1989; 121 (6): 675–80PubMedCrossRef

94.

Peserico A, Angeloni G, Bertoli P, et al. Prevalence of polycystic ovaries in women with acne. Arch Dermatol Res 1989; 281 (7): 502–3PubMedCrossRef

95.

Lucky AW, Biro FM, Huster GA, et al. Acne vulgaris in premenarchal girls: an early sign of puberty associated with rising levels of dehydroepiandrosterone. Arch Dermatol 1994; 130 (3): 308–14PubMedCrossRef

96.

Imperato-McGinley J, Gautier T, Cai LQ, et al. The androgen control of sebum production: studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab 1993; 76 (2): 524–8PubMedCrossRef

97.

Tita P, Spina A, Briguglia G, et al. Clinical features and hormonal characteristics in a case of ovarian arrhenoblastoma. J Endocrinol Invest 1996; 19 (7): 484–7PubMed

98.

Cappel M, Mauger D, Thiboutot D. Correlation between serum levels of insulin-like growth factor 1, dehydroepiandrosterone sulfate, and dihydrotestosterone and acne lesion counts in adult women. Arch Dermatol 2005; 141 (3): 333–8PubMedCrossRef

99.

Thiboutot D, Gilliland K, Light J, et al. Androgen metabolism in sebaceous glands from subjects with and without acne. Arch Dermatol 1999; 135 (9): 1041–5PubMedCrossRef

100.

Walton S, Cunliffe WJ, Keczkes K, et al. Clinical, ultrasound and hormonal markers of androgenicity in acne vulgaris. Br J Dermatol 1995; 133 (2): 249–53PubMedCrossRef

101.

Cibula D, Hill M, Vohradnikova O, et al. The role of androgens in determining acne severity in adult women. Br J Dermatol 2000; 143 (2): 399–404PubMedCrossRef

102.

Hamilton JB. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci 1951; 53 (3): 708–28PubMedCrossRef

103.

Venning VA, Dawber RP. Patterned androgenic alopecia in women. J Am Acad Dermatol 1988; 18 (5 Pt 1): 1073–7PubMedCrossRef

104.

Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex.Br J Dermatol 1977; 97 (3): 247–54PubMedCrossRef

105.

Olsen EA. Disorders of hair growth: diagnosis and treatment. 1st ed. New York: McGraw-Hill, 1994

106.

Olsen EA. Female pattern hair loss. J Am Acad Dermatol 2001; 45 (3 Suppl.): S70–80PubMedCrossRef

107.

Cela E, Robertson C, Rush K, et al. Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol 2003; 49 (5): 439–42CrossRef

108.

Vexiau P, Chaspoux C, Boudou P, et al. Role of androgens in female-pattern androgenetic alopecia, either alone or associated with other symptoms of hyperandrogenism. Arch Dermatol Res 2000; 292 (12): 598–604PubMedCrossRef

109.

Futterweit W, Dunaif A, Yeh HC, et al. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol 1988; 19 (5 Pt 1): 831–6PubMedCrossRef

110.

Miller JA, Darley CR, Karkavitsas K, et al.Low sex-hormone binding globulin levels in young women with diffuse hair loss. Br J Dermatol 1982; 106 (3): 331–6PubMedCrossRef

111.

Kasick JM, Bergfeld WF, Steck WD, et al. Adrenal androgenic female-pattern alopecia: sex hormones and the balding woman. Cleve Clin Q 1983; 50 (2): 111–22PubMed

112.

Schmidt JB, Lindmaier A, Trenz A, et al. Hormone studies in females with androgenic hair loss. Gynecol Obstet Invest 1991; 31 (4): 235–9PubMedCrossRef

113.

Schwartz RA. Acanthosis nigricans. J Am Acad Dermatol1994; 31 (1): 1–19; quiz 20-22PubMedCrossRef

114.

Awata T, Matsumoto C, Momomura K, et al. A 3-basepair in-frame deletion (delta Leu999) in exon 17 of the insulin receptor gene in a family with insulin resistance. J Clin Endocrinol Metab 1994; 79 (6): 1840–4PubMedCrossRef

115.

Taira M, Taira M, Hashimoto N, et al. Human diabetes associated with a deletion of the tyrosine kinase domain of the insulin receptor. Science 1989; 245 (4913): 63–6PubMedCrossRef

116.

Wilgenbus K, Lentner A, Kuckelkorn R, et al. Further evidence that acanthosis nigricans maligna is linked to enhanced secretion by the tumour of transforming growth factor alpha. Arch Dermatol Res 1992; 284 (5): 266–70PubMedCrossRef

117.

Stals H, Vercammen C, Peeters C, et al. Acanthosis nigricans caused by nicotinic acid: case report and review of the literature. Dermatology 1994; 189 (2): 203–6PubMedCrossRef

118.

Gohji K, Hasunuma Y, Gotoh A, et al. Acanthosis nigricans associated with transitional cell carcinoma of the urinary bladder. Int J Dermatol 1994; 33 (6): 433–5PubMedCrossRef

119.

Vassilopoulou-Sellin R, Cangir A, Samaan NA. Acanthosis nigricans and severe insulin resistance in an adolescent girl with thyroid cancer: clinical response to antineoplastic therapy. Am J Clin Oncol 1992; 15 (3): 273–6PubMedCrossRef

120.

Kozlowski LM, Nigra TP. Esophageal acanthosis nigricans in association with adenocarcinoma from an unknown primary site. J Am Acad Dermatol 1992; 26 (2 Pt 2): 348–51PubMedCrossRef

121.

Hud Jr JA, Cohen JB, Wagner JM, et al. Prevalence and significance of acanthosis nigricans in an adult obese population. Arch Dermatol 1992; 128 (7): 941–4CrossRef

122.

Brockow K, Steinkraus V, Rinninger F, et al. Acanthosis nigricans: a marker for hyperinsulinemia. Pediatr Dermatol 1995; 12 (4): 323–6PubMedCrossRef

123.

Dunaif A, Graf M, Mandeli J, et al. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperin-sulinemia. J Clin Endocrinol Metab 1987; 65 (3): 499–507PubMedCrossRef

124.

Panidis D, Skiadopoulos S, Rousso D, et al. Association of acanthosis nigricans with insulin resistance in patients with polycystic ovary syndrome. Br J Dermatol 1995; 132 (6): 936–41PubMedCrossRef

125.

Cruz Jr PD, Hud Jr JA. Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. J Invest Dermatol 1992; 98 (6 Suppl.): 82–5SCrossRef

126.

Torley D, Bellus GA, Munro CS. Genes, growth factors and acanthosis nigricans. Br J Dermatol 2002; 147 (6): 1096–101PubMedCrossRef

127.

Fleming MG, Simon SI. Cutaneous insulin reaction resembling acanthosis nigri-cans. Arch Dermatol 1986; 122 (9): 1054–6PubMedCrossRef

128.

Erickson L, Lipschutz DE, Wrigley W, et al. A peculiar cutaneous reaction to repeated injections of insulin. JAMA 1969; 209 (6): 934–5PubMedCrossRef

129.

McKee PH, Calonje E, Granter SR. Pathology of the skin. 3rd ed. Philadelphia (PA): Elsevier Mosby, 2005

130.

Hermanns-Le T, Scheen A, Pierard GE. Acanthosis nigricans associated with insulin resistance: pathophysiology and management. Am J Clin Dermatol 2004; 5 (3): 199–203PubMedCrossRef

131.

Runnebaum B, Rabe T. New progestogens in oral contraceptives. Am J Obstet Gynecol 1987; 157 (4 Pt 2): 1059–63PubMed

132.

Phillips A, Hahn DW, Klimek S, et al. A comparison of the potencies and activities of progestogens used in contraceptives. Contraception 1987; 36 (2): 181–92PubMedCrossRef

133.

Rebar RW, Zeserson K. Characteristics of the new progestogens in combination oral contraceptives. Contraception 1991; 44 (1): 1–10PubMedCrossRef

134.

Breitkopf DM, Rosen MP, Young SL, et al. Efficacy of second versus third generation oral contraceptives in the treatment of hirsutism. Contraception 2003; 67 (5): 349–53PubMedCrossRef

135.

Arowojolu AO, Gallo MF, Grimes DA, et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2004; (3): CD004425PubMed

136.

Carmina E, Lobo RA. Gonadotrophin-releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission. Hum Reprod 1997; 12 (4): 663–6PubMedCrossRef

137.

Spritzer PM, Lisboa KO, Mattiello S, et al. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxf) 2000; 52 (5): 587–94CrossRef

138.

Vexiau P, Chaspoux C, Boudou P, et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol 2002; 146 (6): 992–9PubMedCrossRef

139.

Van der Spuy ZM, le Roux PA. Cyproterone acetate for hirsutism. Cochrane Database Syst Rev 2003; 4: CD001125PubMed

140.

Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62 (1): 29–38PubMedCrossRef

141.

Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis 2004; 74 (2): 123–30PubMed

142.

Palep-Singh M, Mook K, Barth J, An observational study of Yasmin in the management of women with polycystic ovary syndrome. J Fam Plann Reprod Health Care 2004; 30 (3): 163–5PubMedCrossRef

143.

Batukan C, Muderris II, Ozcelik B, et al. Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. Gynecol Endocrinol 2007 Jan; 23 (1): 38–44PubMedCrossRef

144.

Batukan C, Muderris II. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril 2006; 85 (2): 436–40PubMedCrossRef

145.

Pehlivanov B, Mitkov M. Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome. Eur J Contracept Reprod Health Care 2007 Mar; 12 (1): 30–5PubMedCrossRef

146.

James WD. Clinical practice: acne. N Engl J Med 2005; 352 (14): 1463–72PubMedCrossRef

147.

Lakhani K, Prelevic GM, Seifalian AM, et al. Polycystic ovary syndrome, diabetes and cardiovascular disease: risks and risk factors. J Obstet Gynaecol 2004; 24 (6): 613–21PubMedCrossRef

148.

Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, et al. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 2003; 88 (5): 1927–32PubMedCrossRef

149.

Korytkowski MT, Mokan M, Horwitz MJ, et al. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995; 80 (11): 3327–34PubMedCrossRef

150.

Pazos F, Escobar-Morreale HF, Balsa J, et al. Prospective randomized study comparing the long-acting gonadotropin-releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism. Fertil Steril 1999; 71 (1): 122–8PubMedCrossRef

151.

Rittmaster RS. Differential suppression of testosterone and estradiol in hirsute women with the superactive gonadotropin-releasing hormone agonist leuprolide. J Clin Endocrinol Metab 1988; 67 (4): 651–5PubMedCrossRef

152.

Johansen JS, Riis BJ, Hassager C, et al. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab 1988; 67 (4): 701–6PubMedCrossRef

153.

Matta WH, Shaw RW, Hesp R, et al. Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women. Clin Endocrinol (Oxf) 1988; 29 (1): 45–51CrossRef

154.

Ehrmann DA, Rychlik D. Pharmacologic treatment of polycystic ovary syndrome. Semin Reprod Med 2003; 21 (3): 277–83PubMedCrossRef

155.

Balen AH, Conway GS, Homburg R, et al. Polycystic ovary syndrome. Abingdon (UK): Taylor & Francis, 2005

156.

Jenkins EP, Andersson S, Imperato-McGinley J, et al. Genetic and pharmacological evidence for more than one human steroid 5 alpha-reductase. J Clin Invest 1992; 89 (1): 293–300PubMedCrossRef

157.

Thigpen AE, Silver RI, Guileyardo JM, et al. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 1993; 92 (2): 903–10PubMedCrossRef

158.

Itami S, Kurata S, Takayasu S. 5 alpha-reductase activity in cultured human dermal papilla cells from beard compared with reticular dermal fibroblasts. J Invest Dermatol 1990; 94 (1): 150–2PubMedCrossRef

159.

Thiboutot D, Harris G, Iles V, et al. Activity of the type 1 5 alpha-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol 1995; 105 (2): 209–14PubMedCrossRef

160.

Schwartz JI, Tanaka WK, Wang DZ, et al. MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen. J Clin Endocrinol Metab 1997; 82 (5): 1373–7PubMedCrossRef

161.

Falsetti L, Gambera A, Legrenzi L, et al. Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrinol 1999; 141 (4): 361–7PubMedCrossRef

162.

Moghetti P, Tosi F, Tost A, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2000; 85 (1): 89–94PubMedCrossRef

163.

Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia: Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 1998; 39 (4 Pt 1): 578–89PubMedCrossRef

164.

Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 2000; 43 (5 Pt 1): 768–76PubMedCrossRef

165.

Iorizzo M, Vincenzi C, Voudouris S, et al. Finasteride treatment of female pattern hair loss. Arch Dermatol 2006; 142 (3): 298–302PubMedCrossRef

166.

Leyden J, Bergfeld W, Drake L, et al. A systemic type I 5 alpha-reductase inhibitor is ineffective in the treatment of acne vulgaris. J Am Acad Dermatol2004; 50 (3): 443–7PubMedCrossRef

167.

Corvol P, Michaud A, Menard J, et al. Antiandrogenic effect of spirolactone: mechanism of action. Endocrinology 1975; 97 (1): 52–8PubMedCrossRef

168.

Serafini PC, Catalino J, Lobo RA. The effect of spironolactone on genital skin 5 alpha-reductase activity. J Steroid Biochem 1985; 23 (2): 191–4PubMedCrossRef

169.

Farquhar C, Lee O, Toomath R, et al. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev 2003; 4: CD000194PubMed

170.

Lumachi F, Rondinone R. Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. Fertil Steril 2003; 79 (4): 942–6PubMedCrossRef

171.

Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol 2000; 43 (3): 498–502PubMedCrossRef

172.

Lubbos HG, Hasinski S, Rose LI, et al. Adverse effects of spironolactone therapy in women with acne. Arch Dermatol 1998; 134 (9): 1162–3PubMedCrossRef

173.

Saudan P, Mach F, Perneger T, et al. Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol Dial Transplant 2003; 18 (11): 2359–63PubMedCrossRef

174.

Burke BM, Cunliffe WJ. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br J Dermatol 1985; 112 (1): 124–5PubMedCrossRef

175.

Rushton DH. Quantitative assessment of spironolactone treatment in women with diffuse androgen dependent alopecia. J Cosmet Sci 1991; 42: 317–25

176.

Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol 2005; 152 (3): 466–73PubMedCrossRef

177.

Wysowski DK, Freiman JP, Tourtelot JB, et al. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 1993; 118 (11): 860–4PubMed

178.

Cusan L, Dupont A, Belanger A, et al. Treatment of hirsutism with the pure antiandrogen flutamide. J Am Acad Dermatol 1990; 23 3Pt1 462–9PubMedCrossRef

179.

Cusan L, Dupont A, Gomez JL, et al. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril 1994; 61 (2): 281–7PubMed

180.

Muderris II, Bayram F, Sahin Y, et al. A comparison between two doses of flutamide (250 mg/d and 500 mg/d) in the treatment of hirsutism. Fertil Steril 1997; 68 (4): 644–7PubMedCrossRef

181.

Muderris II, Bayram F, Guven M. A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism. Fertil Steril 2000; 73 (5): 984–7PubMedCrossRef

182.

Muderris II, Bayram F, Guven M. Treatment of hirsutism with lowest-dose flutamide (62.5 mg/day). Gynecol Endocrinol 2000; 14 (1): 38–41PubMedCrossRef

183.

Moghetti P, Castello R, Negri C, et al. Flutamide in the treatment of hirsutism: long-term clinical effects, endocrine changes, and androgen receptor behavior. Fertil Steril 1995; 64 (3): 511–7PubMed

184.

Carmina E, Lobo RA. A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. Clin Endocrinol(Oxf) 2002; 57 (2): 231–4CrossRef

185.

Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril 2003; 79 (1): 91–5PubMedCrossRef

186.

Mansfield R, Galea R, Brincat M, et al. Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril 2003; 79 (4): 956–62PubMedCrossRef

187.

Kelly CJ, Gordon D. The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol 2002; 147 (2): 217–21PubMedCrossRef

188.

Kolodziejczyk B, Duleba AJ, Spaczynski RZ, et al. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000; 73 (6): 1149–54PubMedCrossRef

189.

Pasquali R, Gambineri A, Biscotti D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85 (8): 2767–74PubMedCrossRef

190.

Kazerooni T, Dehghan-Kooshkghazi M. Effects of metformin therapy on hyperan-drogenism in women with polycystic ovarian syndrome. Gynecol Endocrinol 2003; 17 (1): 51–6PubMed

191.

Yilmaz M, Karakoc A, Toruner FB, et al. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol Endocrinol 2005; 21 (3): 154–60PubMedCrossRef

192.

Crave JC, Fimbel S, Lejeune H, et al. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995; 80 (7): 2057–62PubMedCrossRef

193.

Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85 (1): 139–46PubMedCrossRef

194.

Morin-Papunen LC, Koivunen RM, Ruokonen A, et al. Metformin therapy im- proves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998; 69 (4): 691–6PubMedCrossRef

195.

Gambineri A, Patton L, Vaccina A, et al. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab 2006; 91 (10): 3970–80PubMedCrossRef

196.

Bridger T, MacDonald S, Baltzer F, et al. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med 2006; 160 (3): 241–6PubMedCrossRef

197.

Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero JI, et al. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab. Epub 2007 Apr 10

198.

Costello MF, Shrestha B, Eden J, et al. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Hum Reprod 2007 May; 22 (5): 1200–9PubMedCrossRef

199.

Veldhuis JD, Zhang G, Garmey JC. Troglitazone, an insulin-sensitizing thiazolidinedione, represses combined stimulation by LH and insulin of de novo androgen biosynthesis by thecal cells in vitro. J Clin Endocrinol Metab 2002; 87 (3): 1129–33

200.

Azziz R, Ehrmann DA, Legro RS, et al.Troglitazone decreases adrenal androgen in women with polycystic ovary syndrome. Fertil Steril 2003; 79 (4): 932–7PubMedCrossRef

201.

Lemay A, Dodin S, Turcot L, et al. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Hum Reprod 2006; 21 (1): 121–8PubMedCrossRef

202.

Ortega-Gonzalez C, Luna S, Hernandez L, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90 (3): 1360–5PubMedCrossRef

203.

Trivedi NR, Cong Z, Nelson AM, et al. Peroxisome proliferator-activated receptors increase human sebum production. J Invest Dermatol 2006; 126 (9): 2002–9PubMedCrossRef

204.

Romualdi D, Guido M, Ciampelli M, et al. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 2003; 18 (6): 1210–8PubMedCrossRef

205.

Bellot-Rojas P, Posadas-Sanchez R, Caracas-Portilla N, et al. Comparison of metformin versus rosiglitazone in patients with acanthosis nigricans: a pilot study. J Drugs Dermatol 2006; 5 (9): 884–9PubMed

206.

Ciotta L, De Leo V, Galvani F, et al. Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinaemia or lean normoinsulinaemia. Hum Reprod 1999; 14 (12): 2951–8PubMedCrossRef

207.

Lunetta M, Di Mauro M, Le Moli R, et al. Long-term octreotide treatment reduced hyperinsulinemia, excess body weight and skin lesions in severe obesity with acanthosis nigricans. J Endocrinol Invest 1996; 19 (10): 699–703PubMed

208.

Gambineri A, Patton L, Delasio R, et al. Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90 (7): 3854–6PubMedCrossRef

209.

Johnson E, Ebling FJ. The effect of plucking hairs during different phases of the follicular cycle. J Embryol Exp Morphol 1964; 12: 465–74PubMed

210.

Umeda-Ikawa A, Ishii Y, Doi K. Hair cycle induction by hair plucking in Mini rats. Exp Mol Pathol 2006; 80 (3): 306–7PubMedCrossRef

211.

Balfour JA, McClellan K. Topical eflornithine. Am J Clin Dermatol 2001; 2 (3): 197–201; discussion 202PubMedCrossRef

212.

Richards RN, Meharg GE. Electrolysis: observations from 13 years and 140,000 hours of experience. J Am Acad Dermatol 1995; 33 (4): 662–6PubMedCrossRef

213.

Dierickx CC, Grossman MC, Farinelli WA, et al. Permanent hair removal by normal-mode ruby laser. Arch Dermatol 1998; 134 (7): 837–42PubMedCrossRef

214.

Dierickx CC. Hair removal by lasers and intense pulsed light sources. Dermatol Clin 2002; 20 (1): 135–46PubMedCrossRef

215.

Williams R, Havoonjian H, Isagholian K, et al. A clinical study of hair removal using the long-pulsed ruby laser. Dermatol Surg 1998; 24 (8): 837–42PubMedCrossRef

216.

Lask G, Elman M, Slatkine M, et al. Laser-assisted hair removal by selective photothermolysis: preliminary results. Dermatol Surg 1997; 23(9) 737–9 PubMedCrossRef

217.

McDaniel DH, Lord J, Ash K, et al. Laser hair removal: a review and report on the use of the long-pulsed alexandrite laser for hair reduction of the upper lip, leg, back, and bikini region.Dermatol Surg 1999; 25 (6): 425–30PubMedCrossRef

218.

Handrick C, Alster TS. Comparison of long-pulsed diode and long-pulsed alexan-drite lasers for hair removal: a long-term clinical and histologic study. Dermatol Surg 2001; 27 (7): 622–6PubMedCrossRef

219.

Gold MH, Bell MW, Foster TD, et al. Long-term epilation using the EpiLight broad band, intense pulsed light hair removal system. Dermatol Surg 1997; 23 (10): 909–13PubMedCrossRef

220.

Schroeter CA, Groenewegen JS, Reineke T, et al. Hair reduction using intense pulsed light source. Dermatol Surg 2004; 30 (2 Pt 1) 168–73PubMedCrossRef

221.

Fodor L, Menachem M, Ramon Y, et al. Hair removal using intense pulsed light (EpiLight): patient satisfaction, our experience, and literature review.Ann Plast Surg 2005; 54 (1): 8–14PubMedCrossRef

222.

Haider A, Shaw JC. Treatment of acne vulgaris. JAMA 2004; 292 (6): 726–35PubMedCrossRef

223.

Ozolins M, Eady EA, Avery AJ, et al. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial. Lancet 2004; 364 (9452): 2188–95PubMedCrossRef

224.

Becker LE, Bergstresser PR, Whiting DA, et al. Topical clindamycin therapy for acne vulgaris: a cooperative clinical study. Arch Dermatol 1981; 117 (8): 482–5PubMedCrossRef

225.

Dobson RL, Belknap BS. Topical erythromycin solution in acne: results of a multiclinic trial. J Am Acad Dermatol 1980; 3 (5): 478–82PubMedCrossRef

226.

Lesher Jr JL, Chalker DK, Smith Jr JG, et al. An evaluation of a 2% erythromycin ointment in the topical therapy of acne vulgaris. J Am Acad Dermatol 1985; 12 (3): 526–31PubMedCrossRef

227.

Jones EL, Crumley AF. Topical erythromycin vs blank vehicle in a multiclinic acne study. Arch Dermatol 1981; 117 (9): 551–3PubMedCrossRef

228.

Leyden JJ, Hickman JG, Jarratt MT, et al. The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J Cutan Med Surg 2001; 5 (1): 37–42PubMed

229.

Ellis CN, Leyden J, Katz HI, et al. Therapeutic studies with a new combinatio benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis 2001; 67 (2Suppl.):13-20

230.

Lookingbill DP, Chalker DK, Lindholm JS, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol 1997; 37 (4): 590–5PubMedCrossRef

231.

Cooper AJ. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Aust 1998; 169 (5): 259–61PubMed

232.

Dreno B, Reynaud A, Moyse D, et al. Erythromycin-resistance of cutaneous bacterial flora in acne. Eur J Dermatol 2001; 11 (6): 549–53PubMed

233.

Ross JI, Snelling AM, Carnegie E, et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 2003; 148 (3): 467–78PubMedCrossRef

234.

Leyden JJ, McGinley KJ, Cavalieri S, et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983; 8 (1): 41–5PubMedCrossRef

235.

Eady EA, Cove JH, Holland KT, et al. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989; 121 (1): 51–7PubMedCrossRef

236.

Dickinson BD, Altman RD, Nielsen NH, et al. Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol 2001; 98 (5 Pt 1): 853–60PubMedCrossRef

237.

DeRossi SS, Hersh EV. Antibiotics and oral contraceptives. Dent Clin North Am 2002; 46 (4): 653–64PubMedCrossRef

238.

Fazio A. Oral contraceptive drug interactions: important considerations. South Med J 1991; 84 (8): 997–1002PubMedCrossRef

239.

Zachariasen RD. Loss of oral contraceptive efficacy by concurrent antibiotic administration. Women Health 1994; 22 (1): 17–26PubMedCrossRef

240.

Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg 2005; 24 (2): 92–102PubMedCrossRef

241.

Rodondi N, Darioli R, Ramelet AA, et al. High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study.Ann Intern Med 2002; 136 (8): 582–9PubMed

242.

Zane LT, Leyden WA, Marqueling AL, et al. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol 2006; 142 (8): 1016–22PubMedCrossRef

243.

Holte J, Bergh T, Berne C, et al. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol (Oxf) 1994; 41 (4): 463–71CrossRef

244.

Mahabeer S, Naidoo C, Norman RJ, et al. Metabolic profiles and lipoprotein lipid concentrations in non-obese and obese patients with polycystic ovarian disease. Horm Metab Res 1990; 22 (10): 537–40PubMedCrossRef

245.

Wild RA, Painter PC, Coulson PB, et al. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985; 61 (5): 946–51PubMedCrossRef

246.

DeVillez RL, Jacobs JP, Szpunar CA, et al. Androgenetic alopecia in the female: treatment with 2% topical minoxidil solution. Arch Dermatol 1994; 130 (3): 303–7PubMedCrossRef

247.

Jacobs JP, Szpunar CA, Warner ML. Use of topical minoxidil therapy for androgenetic alopecia in women. Int J Dermatol 1993; 32 (10): 758–62PubMedCrossRef

248.

Lucky AW, Piacquadio DJ, Ditre CM, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 2004; 50 (4): 541–53PubMedCrossRef

249.

Kuroki R, Sadamoto Y, Imamura M, et al. Acanthosis nigricans with severe obesity, insulin resistance and hypothyroidism: improvement by diet control. Dermatology 1999; 198 (2): 164–6PubMedCrossRef

250.

Alvarez-Blasco F, Botella-Carretero JI, San Millan JL, et al. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med 2006; 166 (19): 2081–6PubMedCrossRef

251.

Gambineri A, Pelusi C, Genghini S, et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004; 60 (2): 241–9CrossRef

252.

Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999; 84 (4): 1470–4PubMedCrossRef

253.

Akovbyan VA, Talanin NY, Arifov SS, et al. Successful treatment of acanthosis nigricans with etretinate. J Am Acad Dermatol 1994; 31 (1): 118–20PubMedCrossRef

254.

Darmstadt GL, Yokel BK, Horn TD. Treatment of acanthosis nigricans with tretinoin. Arch Dermatol 1991; 127 (8): 1139–4PubMedCrossRef

255.

Hermanns-Le T, Hermanns JF, Pierard GE. Juvenile acanthosis nigricans and insulin resistance. Pediatr Dermatol 2002; 19 (1): 12–4PubMedCrossRef

256.

Bikle DD. Vitamin D: a calciotropic hormone regulating calcium-induced keratinocyte differentiation. J Am Acad Dermatol 1997; 37 (3 Pt 2): S42–52PubMed

257.

Bohm M, Luger TA, Metze D. Treatment of mixed-type acanthosis nigricans with topical calcipotriol. Br J Dermatol 1998; 139 (5): 932–4PubMedCrossRef

258.

Lee HW, Chang SE, Lee MW, et al. Hyperkeratosis of the nipple associated with acanthosis nigricans: treatment with topical calcipotriol. J Am Acad Dermatol 2005; 52 (3 Pt 1): 529–30PubMed

Titel: Dermatologic Manifestations of Polycystic Ovary Syndrome
verfasst von: Amy T. Lee
Dr Lee T. Zane
Publikationsdatum: 01.08.2007
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 4/2007
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.2165/00128071-200708040-00003

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

16.04.2024 | Infektiologie | Nachrichten

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Dermatologic Manifestations of Polycystic Ovary Syndrome

Abstract

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Dupilumab ist mit kutanen T-Zell-Lymphomen assoziiert

Chemotherapie mit Hindernissen

Update Dermatologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2007

The Role of Topical Cyclo-Oxygenase-2 Inhibitors in Skin Cancer

Aggressive Digital Papillary Adenocarcinoma

Efficacy of Oral Fluconazole in the Treatment of Seborrheic Dermatitis

Cancer Concerns with Topical Immunomodulators in Atopic Dermatitis

Vitiligo at the Site of Radiotherapy for Nasopharyngeal Carcinoma

Dermatologic Adverse Effects of Antiretroviral Therapy

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Dupilumab ist mit kutanen T-Zell-Lymphomen assoziiert

Chemotherapie mit Hindernissen

Update Dermatologie